Ilyang Pharmaceutical Co.,Ltd (KRX:007570)
13,080
-80 (-0.61%)
Last updated: Sep 9, 2025, 9:11 AM KST
KRX:007570 Revenue
Ilyang Pharmaceutical Co.,Ltd had revenue of 62.70B KRW in the quarter ending June 30, 2025, with 7.24% growth. This brings the company's revenue in the last twelve months to 276.35B, up 26.66% year-over-year. In the year 2024, Ilyang Pharmaceutical Co.,Ltd had annual revenue of 268.86B with 0.82% growth.
Revenue (ttm)
276.35B
Revenue Growth
+26.66%
P/S Ratio
0.85
Revenue / Employee
414.94M
Employees
666
Market Cap
235.89B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 268.86B | 2.19B | 0.82% |
Dec 31, 2023 | 266.67B | 18.90B | 7.63% |
Dec 31, 2022 | 247.77B | 5.26B | 2.17% |
Dec 31, 2021 | 242.51B | -100.82B | -29.36% |
Dec 31, 2020 | 343.33B | 18.76B | 5.78% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
Celltrion | 3,748.95B |
ALTEOGEN | 158.06B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
Peptron | 5.18B |
PharmaResearch | 449.81B |
ABL Bio | 94.93B |